Monday, January 21, 2019 7:26:03 PM
The shareholder who introduced himself with a "Hi; My name is .... and I have an AMRN problem." I forgot who, but I know all too well about the AMRN problem and it was an awesome introduction.
There are couples who have a variety of stories that go; I/he/she first bought without me/she/he knowing/knowing until/still doesn't know/never will know and I/she/he swore that I/she/he would make/prevent/insist/leave if the other sold or didn't sell for any dollar amount between $4 and $40 except that it blew right through $4 to $10/and now we can't/have to sell if it drops to or gets back up to... A lot of emotional history and anger and tears over interpersonal and monetary family investing decisions. The story has definitely turned around; not that the problems have gone away, but they have been replaced with a higher quality problem... Great stories, especially about where they were on the 24th, and just great people.
We have the slow starters who bought just a little to start and did the homework/loved that the price stayed low the more that they liked the story and they picked up speed and ended up neck deep with the rest of us and either ecstatic over it and intending to hold or concerned about the wonderful opportunity that has opened up and may go away if they don't do the right thing and if only they knew what that was. Most everybody there is long since all in as I met many of the all in pre ADCOM crowd as well as some in for a coupla months then all in for the last 3 months. Different kinds of long since all in. The comfort or unease vary to some degree as some will never let go and others see an unexpected door open and feel it is important to step through it while it is open and feel increasing pressure to do so. This was a widely distributed group of individuals across almost all parameters. We including those scarred deeply by the ADCOM and those who found it last Summer. We also include those who see dark forces and those who see the market's ebb and flow. But we recognize what we have in common and we respect/respected that.
The discussions were good. My current thesis is that we have a stealth catalyst in operation regarding the seemingly inevitable increasing population to whom V would be appropriate and the chronic character of the disease leading to a periodicity or synchronicity to new prescriptions. Whether the individuals health leads to annual, semi annual, or quarterly appointments, each cohort that is associated with a MD who is likely to prescribe V will be contributing at a certain rate as they have their regular appointments, twice that rate, or four times that rate depending until the whole existing omega 3 taking population or newly appropriate for V population has been cycled through once. Add MD's being converted to the cause and you have something that should show up as acceleration on revenue, scripts, or as a second order, share price screens as the momentum screens pick up.
Thanks to Kev and Chris for making this happen in the first place and everyone who showed up and made it a success.
I used to love to play the Craps tables. Not this time. As an AMRN investor, it's like going from a Blackhawk or an F-22 to a hot air balloon. Joe knows what i'm talkin''bout.
Recent AMRN News
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM